The PLCRC substudy Ultra high field 7.0 Tesla MR Spectroscopy to monitor capecitabine metabolism in liver metastases – a proof of concept study - The PLCRC - SPECTRE study

niversity Medical Center Utrecht0 个研究点开始时间: 2016年3月16日最近更新: 2016年8月8日

适应症

试验速览

暂无简介。

•-18 years or older.
•-Patients with liver metastases measurable according to RECIST in metastatic colorectal cancer.
•-Patients that are planned to start with capecitabine (Xeloda®) and bevacizumab (Avastin®) treatment as determined according to Dutch guidelines.
•-Informed consent for longitudinal data collection according to the PLCRC study protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 26
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 26

•- Patients that received any prior systemic therapy for cancer.
•- Patients that received any prior radiotherapy or surgery in the liver.
•- Contra-indications to MRI scanning according to hospitals 7T MRI screening guideline of the UMCU.
•- Patients with severe liver dysfunction.
•- Patients with a life expectancy of < 3 months.
•- Pregnant or lactating women.
•- Patients with claustrofobia.

发起方